ISS-peanut allergen conjugate - Dynavax

Drug Profile

ISS-peanut allergen conjugate - Dynavax

Alternative Names: Ara h 2-ISS allergen conjugate

Latest Information Update: 20 Jul 2007

Price : $50

At a glance

  • Originator Dynavax Technologies
  • Class Allergens; Glycoproteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Peanut hypersensitivity

Most Recent Events

  • 20 Jul 2007 This programme is still in active development
  • 22 Mar 2005 Dynavax Technologies and UCB have terminated their development and commercialisation collaboration in seasonal allergy products worldwide
  • 18 Nov 2004 Preclinical data from a media release have been added to the Immunological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top